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Objective. The identification of novel autoanti-
bodies in juvenile dermatomyositis (DM) may have
etiologic and clinical implications. The aim of this study
was to describe autoantibodies to a 140-kd protein in
children recruited to the Juvenile DM National Registry
and Repository for UK and Ireland.
Methods. Clinical data and sera were collected
from children with juvenile myositis. Sera that recog-
nized a 140-kd protein by immunoprecipitation were
identified. The identity of the p140 autoantigen was
investigated by immunoprecipitation/immunodepletion,
using commercial monoclonal antibodies to NXP-2,
reference anti-p140, and anti-p155/140, the other auto-
antibody recently described in juvenile DM. DNA sam-
ples from 100 Caucasian children with myositis were
genotyped for HLA class II haplotype associations and
compared with those from 864 randomly selected UK
Caucasian control subjects.
Results. Sera from 37 (23%) of 162 patients with
juvenile myositis were positive for anti-p140 autoanti-
bodies, which were detected exclusively in patients with
juvenile DM and not in patients with juvenile DM–
overlap syndrome or control subjects. No anti-p140
antibody–positive patients were positive for other rec-
ognized autoantibodies. Immunodepletion suggested
that the identity of p140 was consistent with NXP-2 (the
previously identified MJ autoantigen). In children with
anti-p140 antibodies, the association with calcinosis was
significant compared with the rest of the cohort (cor-
rected P < 0.005, odds ratio 7.0, 95% confidence interval
3.0–16.1). The clinical features of patients with anti-
p140 autoantibodies were different from those of chil-
dren with anti-p155/140 autoantibodies. The presence of
HLA–DRB1*08 was a possible risk factor for anti-p140
autoantibody positivity.
Conclusion. This study has established that anti-
p140 autoantibodies represent a major autoantibody
subset in juvenile DM. This specificity may identify a
further immunogenetic and clinical phenotype within
the juvenile myositis spectrum that includes an associ-
ation with calcinosis.
Juvenile dermatomyositis (DM) is the most com-
mon of the idiopathic inflammatory myopathies (IIMs)
of children. The reported incidence is 0.8–4.1 per mil-
lion children per year (1–3). Juvenile DM is chronic,
potentially debilitating, and can be associated with sig-
nificant morbidity. Due to the heterogeneity of the
condition with multisystem disease, the clinical outcome
(and thus prognosis) is difficult to predict. Certain
clinical features, such as skin ulceration, calcinosis,
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1807gastrointestinal involvement, and respiratory disease,
have been proposed as predictors of a severe disease
course in juvenile DM (4–7).
The precise etiology of IIMs is unknown, but
there is increasing evidence to suggest an important role
for autoimmunity. Knowledge of an autoantibody pro-
file is an important cornerstone in the diagnosis of
patients with a wide variety of autoimmune connective
tissue disorders. Myositis-specific autoantibodies
(MSAs) are being observed with increasing frequency in
adult patients with IIM. There is now increasing evi-
dence that MSAs are associated with homogeneous
clinical subsets within the IIM spectrum, which can help
predict clinical outcomes (8–10). For example, autoan-
tibodies directed against the aminoacyl–transfer RNA
synthetases (aaRS) form the largest group of MSAs in
adult IIM and are associated with the antisynthetase
syndrome (10,11). Other well-described MSAs in adult
IIM that are associated with specific clinical manifesta-
tions include antisignal recognition particle (anti-SRP)
and anti–Mi-2 autoantibodies (10).
To date, MSAs in juvenile myositis, including
juvenile DM, have been less well characterized. Previous
reports have described myositis-associated autoantibod-
ies (MAAs), including anti–PM-Scl and anti–U1 RNP,
in juvenile DM overlap syndromes (12). Anti–Mi-2 has
been described more frequently, but this autoantibody
specificity and others such as aaRS and anti-SRP are
detected in a relatively small number of juvenile myositis
cases (13–15). Recently, our group and other investiga-
tors have observed that autoantibodies to a 155-kd
protein and a 155/140-kd doublet protein are a major
serologic subset in juvenile DM (16,17). In addition,
anti-p155/140 autoantibodies appear to define a distinct
clinical phenotype within the juvenile DM spectrum
(17). A further autoantibody termed anti-MJ, which
targets a 140-kd protein, has been described in a US
cohort of patients with juvenile DM (18). The MJ
autoantigen was recently identified as nuclear matrix
protein NXP-2 (19).
In this study, we describe the prevalence, clinical
associations, and immunogenetic associations of autoan-
tibodies targeting a p140 protein in children recruited to
the Juvenile DM Registry and Repository for UK and
Ireland (JDRR) (for review, see refs. 6 and 12). We
demonstrate that anti-p140 and anti-p155/140 are differ-
ent autoantibody subsets and investigate the identity of
the p140 target, which is likely to be the same as the
previously identified MJ autoantigen NXP-2 (also
termed MORC3) (18,19).
PATIENTS AND METHODS
Patients and sera. The JDRR has recruited patients
with juvenile-onset myositis, all of whom were younger than
age 16 years at the time of disease onset and diagnosis, from 10
centers around the UK (6). All patients had probable or
definite myositis according to the diagnostic criteria described
by Bohan and Peter (20,21). Demographic and serial clinical
data were recorded at the time of diagnosis and prospectively
at subsequent visits (approximately every 6 months). The
clinical information recorded comprised specific cutaneous
manifestations, including the presence of Gottron’s lesions,
skin ulceration, edema, calcinosis, and the distribution of skin
rash over the body. Details on muscle involvement included
muscle enzymes (creatine kinase [CK] and lactate dehydroge-
nase [LDH]) and the Childhood Myositis Assessment Scale
(CMAS) (22) at baseline. Data were stored onto a central
database, using anonymous codes. Serum and DNA samples
were obtained at the time of diagnosis and stored at 20°C
until required. Serum samples for serologic typing were avail-
able from 162 children recruited to the registry. DNA for
genotyping was available from 100 Caucasian children with
juvenile DM.
Clinical data were available for 160 children, 74% of
whom were female. The median age at disease onset was 6
years (interquartile range [IQR] 3–9 years), and the median
age at the time of diagnosis was 7 years (IQR 4–10 years). For
this study, the median followup period from disease onset to
the time of data analysis was 48 months (IQR 33–72 months)
for the overall cohort. One hundred thirty-seven children had
juvenile DM. Juvenile DM–scleroderma (juvenile DM–SSc)
overlap syndrome is well recognized in children with juvenile
DM who have a history of Raynaud’s phenomenon, sclerodac-
tyly, and other sclerodermatous skin changes. In this study, 21
children were defined as having juvenile DM–SSc overlap
syndrome, with 2 or more of the above-mentioned features.
Two children were defined as having other forms of juvenile
myositis, not specifically juvenile DM or juvenile DM–SSc
overlap syndrome.
Sera from 124 juvenile disease control subjects (20 with
scleroderma/linear scleroderma, 8 with systemic lupus ery-
thematosus, and 96 with juvenile idiopathic arthritis) were also
analyzed. No sera from healthy children were available, reflect-
ing the ethical difficulties in studies of this nature. Therefore,
sera from 50 healthy adult control subjects were also sero-
typed.
Ethics approval. All patients or their parents gave fully
informed written/parental consent to participate and provide
biologic samples, according to the Declaration of Helsinki,
under both national multicenter and local ethics committee
regulations.
Indirect immunofluorescence. Indirect immunofluo-
rescence was performed by standard methods, using Hep-2
cells and fluorescein-labeled anti-human IgG (Sigma, Poole,
UK).
Protein immunoprecipitation (IP). IP with K562 cell
extracts was performed as previously described (23). Briefly, 10
l of sera was mixed with 2 mg protein A–Sepharose beads
(Sigma) in IP buffer (10 mM Tris HCl, pH 8.0, 500 mM NaCl,
0.1% volume/volume Igepal) at room temperature for 30
minutes. Beads were washed in IP buffer prior to the addition
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35S-methionine–labeled K562 cell extract. Samples
were mixed at 4°C for 2 hours. Beads were washed in IP buffer
followed by Tris buffered saline buffer (10 mM Tris HCl, pH
7.4, 150 mM NaCl) before being resuspended in 50 l sodium
dodecyl sulfate (SDS) sample buffer (Sigma). After heating,
proteins were fractionated by 10% SDS–polyacrylamide gel
electrophoresis, enhanced, fixed, and dried. Labeled proteins
were analyzed by autoradiography.
IP with mouse monoclonal anti–NXP-2 and immu-
nodepletion experiments. Ten microliters of anti-p140–
positive sera or 50 l of commercial mouse antibody to NXP-2
(MORC3) (Medical and Biological Laboratories, Nagoya,
Japan) was mixed with 100 l of prewashed protein G Dyna-
beads (Dynal, Liverpool, UK) in sodium phosphate (pH 8.1,
0.1M) at room temperature for 30 minutes. The antigens were
immunoprecipitated as described for IP, using
35S-
methionine–labeled K562 cell extracts. Immunodepletion was
performed to ascertain whether the IP pattern observed with
anti-p140–positive juvenile DM sera and the commercial anti-
body to NXP-2 was attributable to precipitation of the same
antigen. This method was also used to confirm that anti-p155/
140–positive juvenile DM sera target a different protein (17).
Cell extracts were depleted of autoantibody targets, using a
reference anti-p140–positive juvenile DM serum, reference
anti-p155/140–positive juvenile DM serum, and normal serum
as a negative control.
Briefly, duplicate samples, each of which contained 10
mg protein A–Sepharose beads (when preparing predepleted
p140 cell extract for IP with commercial anti–NXP-2, 150 l
prewashed protein G Dynabeads was used) in 1 ml IP buffer
and 50 l anti-p140 serum (or 50 l anti-p155/140 serum) were
mixed at room temperature for 30 minutes. The beads were
washed in IP buffer, and 1 tube (tube A) was placed on ice,
while 120 l
35S-methionine–labeled K562 cell extract and 380
l IP buffer were added to tube B. Tube B was mixed at 4°C for
2 hours; the supernatant was transferred to the corresponding
tube A, which was then mixed at 4°C for an additional 2 hours.
The supernatant from the corresponding tube A (i.e., p140
antigen–depleted cell extract or p155/140 antigen–depleted
cell extract) was stored at 80°C. IP with depleted cell extracts
was completed using 50 l commercial anti–NXP-2, different
anti-p140 sera (10 l), or different anti-p155/140 sera (10 l).
HLA typing. DNA samples from Caucasian patients
with juvenile DM were extracted from blood samples and
analyzed using a standard phenol–chloroform method. Pa-
tients were broad-typed for the HLA–DRB1 and DQB1 loci
using a commercially available polymerase chain reaction
sequence-specific oligonucleotide probe typing system (Dynal,
Hamburg, Germany), as previously described (24). The HLA–
DQA1 data were derived from the DRB1 and DQB1 results,
using well-documented Caucasian haplotype tables (25).
Statistical analysis. Clinical and HLA allelic associa-
tions were derived from 2  2 contingency tables, using the
chi-square test or 2-tailed Fisher’s exact test when the value for
individual cells was 5. Significant results were expressed as
odds ratios (ORs) with exact 95% confidence intervals (95%
CIs). P values were adjusted using the Bonferroni correction
when comparing clinical associations. Uncorrected P values
are presented for possible immunogenetic associations. Hap-
lotypes were estimated for selected loci using the expectation-
maximization algorithm, as implemented in HelixTree (version
3.1.2; Golden Helix, Bozeman, MT) (22). SPSS for Windows
(version 14; SPSS, Chicago, IL) (for clinical data) and Stata
(release 9; Stata Corp., College Station, TX) (for HLA data)
were used to perform statistical analysis.
RESULTS
Identification of anti-p140 autoantibodies in ju-
venile DM sera. Following IP, sera from several patients
with juvenile DM recognized a distinct protein band with
a molecular weight of 140 kd (Figure 1). No anti-
p140–positive sera were observed to immunoprecipitate
any other known MSAs or MAAs. A weak nonspecific
nuclear pattern (or, in some cases, antinuclear antibody
negativity) was observed by indirect immunofluores-
cence in all anti-p140 sera (data not shown). Anti-p140
was not detected in any of the juvenile disease control
sera or healthy adult control sera.
Confirmation of the p140 autoantigen. Our re-
sults suggest that the p140 protein targeted by juvenile
DM sera in our study has the same identity as the MJ
antigen, NXP-2 (19). Using a commercial antibody
raised against NXP-2, IP resulted in the precipitation of
a band with the same molecular weight and IP pattern as
those observed in anti-p140–positive juvenile DM sera
(Figure 2, lane 3). When the cell extract was predepleted
with juvenile DM anti-p140–positive sera, the IP band
Figure 1. Immunoprecipitation of p140 autoantigens. The autoradio-
gram shows the results of 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis of immunoprecipitates of
35S-methionine–labeled
K562 cell extracts, using normal serum (lane 1), anti-p155/140–positive
juvenile dermatomyositis (DM) serum (lane 2), and different anti-
p140–positive juvenile DM sera (lanes 3–14).
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detectable (Figure 2, lane 4). The immunodepletion
results support the co-identity of the p140 protein
precipitated by different anti-p140–positive juvenile sera
(complete data not shown). Figure 3 (lanes 5 and 6)
shows an example in which the 140-kd band is no longer
detectable following IP with anti-p140 sera (designated
“1”) and using predepleted reference p140 cell extract
(designated “2”). In addition, immunodepletion con-
firmed that anti-p140 sera target a different protein to
juvenile DM sera that recognizes the p155/140 doublet
protein (Figure 3, lanes 1–4, showing that the respective
bands are still present following IP).
Clinical associations of anti-p140 autoantibod-
ies. Of 162 juvenile myositis sera serotyped by IP, 37
(23%) had anti-p140 autoantibodies. This autoantibody
specificity was observed exclusively in sera from patients
with juvenile DM, with a frequency of 27%. Anti-p140
was not detected in any sera from patients with juvenile
DM–SSc overlap syndrome. Selected clinical features of
anti-p140–positive patients compared with the overall
anti-p140–negative juvenile myositis cohort are shown in
Table 1. There was no significant difference in the
female-to-male ratio, the age at the time of disease onset
or diagnosis, and disease duration (from disease onset to
the time of this study) between anti-p140–positive and
anti-p140–negative patients. Overall, there was no sig-
Figure 3. Immunodepletion experiments with anti-p140 and anti-
p155/140. The autoradiogram shows the results of 10% sodium dodecyl
sulfate–polyacrylamide gel electrophoresis of immunoprecipitates, us-
ing different anti-p140–positive juvenile DM sera (lanes 1, 2, 5, and 6)
and anti–p155/140–positive juvenile DM sera (lanes 3 and 4). Immu-
noprecipitation was performed with
35S-methionine–labeled K562 cell
extracts predepleted with either reference anti-p140–positive juvenile
DM serum or reference anti-p155/140–positive juvenile DM serum.
See Figure 2 for definitions.
Figure 2. Immunodepletion of commercial NXP-2. The autoradio-
gram shows the results of 10% sodium dodecyl sulfate–polyacrylamide
gel electrophoresis of immunoprecipitates of
35S-labeled K562 cell
extracts using normal sera (NS; lane 1), reference anti-p140–positive
juvenile dermatomyositis (DM) serum (lane 2), and commercial
anti–NXP-2 (lane 3). Lane 4 shows the results of immunoprecipitation
using commercial anti–NXP-2 with
35S-methionine–labeled cell extract
predepleted with reference anti-p140–positive juvenile DM serum. IPP
 immunoprecipitation.
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skin ulceration, edema, or the distribution of rash,
except anti-p140–positive children had no rashes on the
trunk compared with anti-p140–negative children (cor-
rected P [Pcorr]  0.02). Anti-p140–positive cases were
significantly associated with the presence of subcutane-
ous calcinosis compared with anti-p140–negative cases
(Pcorr  0.005, OR 7.0, 95% CI 3.0–16.1). There was no
significant difference between other clinical features
when comparing anti-p140–positive patients and anti-
p140–negative patients, including the baseline CK level,
the CMAS score, the Childhood Health Assessment
Questionnaire (C-HAQ) score (26), the physician’s
global assessment scale (PGA) score, and the presence
of arthritis, Raynaud’s phenomenon, dysphagia, mouth
ulcers, and alopecia (data not shown).
Possible clinical differences were noted when
anti-p140–positive patients were compared with anti-
p155/140–positive patients (Table 1). Overall, the age at
disease onset or diagnosis and disease duration (for
anti-p140–positive patients, median 48 months [IQR
34–72]; for anti-p155/140–positive patients, median 52
months [IQR 36–84]) were similar between the 2 auto-
antibody groups. Compared with anti-p155/140–positive
patients, anti-p140–positive patients had an association
with calcinosis (14% versus 54%; Pcorr  0.015, OR 7.1
[95% CI 2–25]). In contrast, anti-p155/140–positive pa-
tients compared with the anti-p140–positive group had a
higher frequency of ulceration and cutaneous edema;
however, this result was not significant after correcting
for multiple comparisons. The distribution of rash was
wider on the trunk (Pcorr  0.005) and over the small
joints (Pcorr  0.05, OR 13.5 [95% CI 2–113]) in
anti-p155/140–positive children compared with anti-
p140–positive patients.
At the time of diagnosis, anti-p140–positive com-
pared with anti-p155/140–positive children had a non-
significantly lower CK level (median 202 IU/liter [IQR
76–2,142] versus median 571 IU/liter [IQR 234–2,495])
and LDH level (median 845 IU/liter [IQR 710–1,620]
versus median 1,171 IU/liter [IQR 736–1,647]). In addi-
tion, anti-p140–positive patients had a higher CMAS
score at the time of diagnosis compared with anti-p155/
140–positive patients (median 42 [IQR 23–49] versus
median 16 [IQR 7–38]; P not significant after adjustment
for multiple comparisons). There was a nonsignificant
trend toward a lower baseline C-HAQ score and PGA
score in the anti-p140 group compared with the anti-
p155/140 group (median C-HAQ score 1.31 [IQR 0.75–
1.63] versus median 1.63 [IQR 0.78–2.34]); median PGA
score 5 [IQR 3–7.4] versus median 7.3 [IQR 5–7.8]).
However, these results need to be interpreted in the
context that these data were recorded for only a small
number of patients at the time of diagnosis.
Immunogenetic associations of anti-p140 auto-
antibodies. HLA–DRB1*08 was a possible immunoge-
netic risk factor and was present in 23.5% of 17 anti-
p140–positive patients compared with 5.4% of 864
control subjects (P  0.01, OR 5.3 [95% CI 1.2–18.1]).
HLA–DRB1*08 was observed in 4.8% of 83 anti-p140–
negative patients and in 11.8% of 18 anti-p155/140–
positive patients. DQA1*06 was also observed more
frequently in anti-p140–positive patients (11.8% of 17
patients compared with 1% of 192 control subjects; P 
0.03, OR 12.7 [95% CI 0.8–181.0]). This haplotype was
not observed in anti-p140–negative or anti-p155/140–
positive patients. However, these results were not signif-
icant after correcting for multiple comparisons.
DISCUSSION
There is now increasing evidence that MSAs are
associated with (and thus can identify) clinical subsets
Table 1. Selected clinical features of anti-p140–positive patients
with juvenile DM compared with anti-p140–negative juvenile DM
patients with myositis and anti-p155/140–positive juvenile DM
patients*
Characteristic
Anti-p140
positive
(n  37)†
Anti-p140
negative
(n  125)†
Anti-p155/140
positive
(n  28)
Age at disease onset,
median (IQR) years
6 (2–10) 6 (4–9) 6 (4–10)
Age at diagnosis, median
(IQR) years
7 (4.5–10.3) 7 (4–10) 7 (4–10)
Female sex 72 74 57
Type of skin lesion
Gottron’s papules 85 82 100
Ulceration 34 23 57
Edema 35 35 64
Calcinosis 54‡ 15 14
Lipoatrophy 18 13 18
Distribution of skin rash
Periorbital 79 69 96
Periungal 64 67 86
Small joints 67§ 72 96
Large joints 52 51 75
Trunk 0¶ 18 32
* Except where indicated otherwise, values are the percent of patients.
DM  dermatomyositis; IQR  interquartile range.
† Not all patients had clinical data available for each feature.
‡ Corrected P (Pcorr)  0.005, odds ratio (OR) 7.0, 95% confidence
interval (95% CI) 3.0–16.1 versus anti-p140–negative patients, and
Pcorr  0.015, OR 7.1, 95% CI 2–25 versus anti-p155/140–positive
patients.
§ Pcorr  0.05, OR 13.5, 95% CI 2–113 versus anti-p155/140–positive
patients.
¶ Pcorr  0.02 versus anti-p140–negative patients, and Pcorr  0.005
versus anti-p155/140–positive patients.
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specific genetic and serologic profiles may also be asso-
ciated with clinical phenotypes in juvenile DM (12–17).
In this report, we describe the novel autoantibody
specificity, anti-p140, in a UK cohort study of patients
with juvenile DM. The presence of anti-p140 autoanti-
bodies represents a major serologic subset in juvenile
myositis; it was observed exclusively in juvenile DM and
was not detected in any cases of juvenile DM–SSc
overlap syndrome. All anti-p140–positive sera recog-
nized the same polypeptide and did not immunoprecipi-
tate any other known myositis autoantigens, including
the anti-p155/140 autoantibody (16,17). Combining the
data from our UK juvenile DM cohort studies, anti-p140
and anti-p155/140 autoantibodies were detected in
40% of patients with juvenile DM, in contrast to a
much lower frequency of anti–Mi-2 and other myositis-
specific or associated autoantibodies, as previously re-
ported (12–15).
The confirmation of a further serologic subset in
juvenile DM appears to have important clinical implica-
tions. Anti-p140 positivity was significantly associated
with the presence of calcinosis when compared with the
overall juvenile myositis cohort. In addition, anti-p140
and anti-p155/140 appear to define juvenile DM into 2
serologic subsets with more homogeneous clinical fea-
tures. The results of this study, combined with our
previous work (17), suggest that anti-p155/140–positive
patients have a wider distribution of skin disease, more
cutaneous complications including edema or ulceration,
and possibly overall higher disease activity but a signif-
icantly lower frequency of calcinosis compared with
anti-p140–positive patients.
The clinical differences observed between anti-
p140–positive patients, anti-p155/140–positive patients,
and patients with neither of these specificities are not
explained by differences in the time to disease onset or
disease duration. This is an interesting observation,
because a factor suggested to influence the development
of calcinosis is persistent active disease, including
chronic cutaneous inflammation (27–29). The associa-
tion between serotype and clinical phenotype suggests
that the targeted autoantigens p140 and p155/140 may
play a role in the pathogenesis of skin and soft tissue
complications in juvenile DM. In addition, HLA–
DRB1*08 is a possible immunogenetic risk factor for the
development of anti-p140 autoantibodies in Caucasian
children with juvenile DM.
Based on previous work that showed an associa-
tion with the tumor necrosis factor  (TNF) 308A
allele, increased production of TNF, and calcinosis
(28), future studies to investigate for other potential
susceptibility genes, including TNF polymorphisms, in
juvenile DM patients with anti-p140 or anti-p155/140
autoantibodies would be of major interest.
The p140 protein targeted by an autoimmune
response in our juvenile DM cohort study is consistent
with NXP-2, the MJ autoantigen described in prelimi-
nary reports in a US juvenile DM cohort (18,19). NXP-2
has nuclear matrix–binding, RNA-binding, and coiled-
coil domains that are structurally separated, which may
implicate a role in diverse nuclear functions including
regulation of transcriptional and RNA metabolism (30).
Previously described DM-specific autoantigen targets in
children and adults, Mi-2 and p155/140 (p155; transcrip-
tion intermediary factor 1 gamma) (31,32), are nuclear
proteins that also mediate gene transcription. It is of
further interest to note that autoantibodies to small
ubiquitin-like modifier activating enzyme (SAE), which
is involved in posttranscriptional modification termed
sumoylation, have been described in adult DM (33). To
date, anti-SAE autoantibodies have not been detected in
juvenile myositis sera (Gunawardena H: unpublished
observations). However, NXP-2 has been shown to be a
sumoylation target involved in transcriptional repression
(34), which may suggest potential shared pathogenic
mechanisms in both juvenile and adult DM.
In conclusion, anti-p140 autoantibody is a clini-
cally important serologic marker that is observed with a
high frequency in patients with juvenile DM and is
associated with calcinosis, a complication of the disease
that confers significant morbidity. In the future, routine
testing for these novel autoantibodies (anti-p140 and
anti-p155/140) at the time of disease onset could have
prognostic value and identify those children who are at
risk of more severe disease, which may influence man-
agement. Furthermore, increasing our understanding of
autoimmune targets and their relationship to the clinical
phenotype in juvenile myositis may provide further
insight into pathogenic pathways that in turn will stim-
ulate new therapeutic approaches.
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